Illumina (ILMN) : Fridays money flow data in Illumina (ILMN) suggests that the bulls made the most of the weakness in the stock. The inflow of money into the stock on upticks was $29.23 million, whereas, $18.11 million worth of transactions were done on downticks. The ratio between the two, uptick and downtick stood at 1.61, in favor of the bulls. The total money flow into the stock was $11.12 million clearly indicating that the smart money has been buying into the stock on weakness.
In comparison, the money flow in block deals was $8.99 million. The total value of block trades done on upticks was $8.99 million. Illumina (ILMN) fell $0.66 and traded at $167.9, down -0.39% for the day, over previous days close. On a weekly basis, the shares are -2.5% over the previous weeks close.
The company Insiders own 1.6% of Illumina shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -17.73% . Institutional Investors own 95.27% of Illumina shares. During last six month period, the net percent change held by insiders has seen a change of -22.7%.
In a related news,The director of Illumina Inc, Flatley Jay T sold 20,000 shares at $173.56 on August 23, 2016. The Insider selling transaction had a total value worth of $3,471,200. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Illumina (NASDAQ:ILMN): stock was range-bound between the intraday low of $167.25 and the intraday high of $169.955 after having opened at $169.93 on Fridays session. The stock finally closed in the red at $169.93, a loss of -0.39%. The stock remained in the red for the whole trading day. The total traded volume was 503,289 shares. The stock failed to cross $169.955 in Fridays trading. The stocks closing price on Thursday was $168.56.
Illumina (ILMN) has risen sharply, recording gains of 0.82% in the past 4 weeks. However, the stock has corrected -2.5% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 0.96% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
Illumina, Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms, reagent kits and scanning equipment. Its customers include genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories, pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research, including de novo sequencing, genetic variation analysis, epigenetics and targeted screening, among others. It also provides products and services for other life sciences applied markets, such as agrigenomics. It also offers Clarity Run Manager, Clarity LIMS Silver and Clarity LIMS Gold.